Most variants of ACVRL1 in HHT are attributable to mutations in the conserved residues of the kinase domain, and there is often a loss of kinase activity that disrupts BMP9- and SMAD4-dependent signaling. This evidence concerns the gene SMAD4 and hereditary hemorrhagic telangiectasia.